BioMarin Pharmaceutical Inc - Company Profile
Powered by
All the data and insights you need on BioMarin Pharmaceutical Inc in one report.
- Save hours of research time and resources with
our up-to-date BioMarin Pharmaceutical Inc Strategy Report
- Understand BioMarin Pharmaceutical Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
BioMarin Pharmaceutical Inc (BioMarin) is a biotechnology company that develops and commercializes innovative medicines for the treatment of rare genetic diseases and medical conditions such as Duchenne muscular dystrophy (DMD), achondroplasia, phenylketonuria (PKU), late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. The company focuses on developing breakthrough treatments for debilitating and life-threatening diseases. Its product category consists of multiple clinical and preclinical offerings which include Naglazyme-Mucopolysaccharidosis Type VI (MPS VI), Aldurazyme-MPS I and others. The company operates through its manufacturing facility in Novato, California. It conducts business operations in the US, Europe, Latin America, the Middle East, and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.
BioMarin Pharmaceutical Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Naglazyme-Mucopolysaccharidosis Type VI (MPS VI) | VOXZOGO |
Aldurazyme-MPS I | Palynnziq |
Kuvan-Phenylketonuria (PKU) | Brineura |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Financing Agreements | In December, the company secured an investment from Elliott Investment Management. |
2023 | Contracts/Agreements | In November, the company announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement amount for ROCTAVIAN (valoctocogene roxaparvovec-rvox) for people with severe hemophilia A. |
2023 | Plans/Strategy | In June, the company announced its plans to present new data from the ROCTAVIAN gene therapy clinical trial program. |
Competitor Comparison
Key Parameters | BioMarin Pharmaceutical Inc | Biogen Inc | Amicus Therapeutics Inc | Protalix BioTherapeutics Inc | Enzon Pharmaceuticals Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Novato | Cambridge | Philadelphia | Hackensack | Cranford |
State/Province | California | Massachusetts | Pennsylvania | New Jersey | New Jersey |
No. of Employees | 3,401 | 7,570 | 517 | 208 | - |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Richard A. Meier | Chairman | Executive Board | 2023 | - |
Alexander Hardy | Chief Executive Officer; Director; President | Executive Board | 2023 | - |
Brian R. Mueller | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | 49 |
Erin Burkhart | Chief Accounting Officer; Vice President | Senior Management | 2022 | - |
C. Greg Guyer, Ph.D | Chief Technology Officer; Executive Vice President - Global Manufacturing and Technical Operations. | Senior Management | 2020 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward